0.13
-0.0005(-0.38%)
Currency In USD
| Previous Close | 0.13 |
| Open | 0.13 |
| Day High | 0.13 |
| Day Low | 0.13 |
| 52-Week High | 0.97 |
| 52-Week Low | 0.1 |
| Volume | 325 |
| Average Volume | 73,072 |
| Market Cap | 13.6M |
| PE | -0.06 |
| EPS | -2.27 |
| Moving Average 50 Days | 0.18 |
| Moving Average 200 Days | 0.31 |
| Change | -0 |
If you invested $1000 in NKGen Biotech, Inc. Common Stock (NKGN) since IPO date, it would be worth $23.2 as of September 15, 2025 at a share price of $0.133. Whereas If you bought $1000 worth of NKGen Biotech, Inc. Common Stock (NKGN) shares 1 year ago, it would be worth $177.85 as of September 15, 2025 at a share price of $0.133.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Data not available
NKGen Biotech, Inc. Announces Completion of NKMax Co., Ltd. Acquisition; Gains Full Control of Global Manufacturing and Intellectual Property Assets
GlobeNewswire Inc.
Sep 09, 2025 12:05 PM GMT
NKGen acquires controlling stake in NKMax, marking a pivotal moment in its transformation into a fully integrated, self-sustaining, cell therapy company with global manufacturing and IP control.Approximately $16.9 million paid to acquire 65% equity s
NKGen Biotech To Present on Allogeneic Enhanced NK Cells without Lymphodepletion in Solid Tumors at the 13th Annual Immuno-Oncology Summit
GlobeNewswire Inc.
Aug 06, 2025 12:00 PM GMT
SANTA ANA, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural
NKGen Biotech Presents Troculeucel Mechanism of Action with Corresponding Phase 1 Biomarker Data at the Alzheimer’s Association International Conference 2025
GlobeNewswire Inc.
Jul 28, 2025 12:05 PM GMT
Troculeucel, a cryopreserved autologous, non-genetically modified NK cell product, appears to cross the blood brain barrier (BBB) via CXCR3, to reduce neuroinflammation via a simple IV administration. Troculeucel was shown to internalize and digest a